On the afternoon of August 20, the company successfully held its 2024 Annual Shareholders 'Meeting and the 15th Meeting of the 6th Board of Directors at the Marketing Center. Shareholder representatives from Hunan Pharmaceutical Development Investment Group, the Provincial Academy of Chinese Medicine, Xiangjiang Industry, Xiangxue Pharmaceutical, and the Health and Wellness Fund, along with several individual shareholders and company directors and supervisors, attended the meeting. Zhao Zhihai, Deputy General Manager of the Group, attended and delivered a speech, while Shen Fanshun, the company's Party Branch Secretary and Chairman, chaired the meeting.

Prior to the meeting, shareholder representatives, directors, and supervisors toured the marketing center's exhibition hall and office areas. They unanimously praised the new location's prime location and comprehensive facilities.

The meeting reviewed and deliberated on the following proposals: the Board of Directors' 2023 Annual Work Report, the 2024 Semi-Annual Work Report, the 2024 Annual Business Plan, the 2024 Annual Investment Plan, the 2023 Annual Financial Settlement Report, the 2024 Annual Financial Budget Report, and the 2023 Annual Profit Distribution Plan.

At the meeting, the representatives of shareholders, directors and supervisors fully affirmed the work and achievements made by the company during the transformation process, expressed confidence in the company's future development, and put forward requirements and suggestions for the next stage of development.

Zhao Zhihai, representing Hunan Pharmaceutical Development Investment Group, expressed gratitude to shareholders for their long-term support of Chun Guang Jiu Hui's development. He stated that the company has largely achieved its transformation and development goals. In the next phase, Chun Guang Jiu Hui will focus on new traditional Chinese medicine decoction pieces as its core business, concentrate on its main responsibilities, and develop its own competitive products. The company will actively develop markets and ensure product supply for benchmark medical institutions. It will also prioritize cultivating and attracting skilled craftsmen, significantly enhance production technology, accelerate capacity expansion, and achieve rapid and stable growth. Additionally, the company will persist in scientific research and innovation, strengthen collaboration with the Provincial Academy of Chinese Medicine and the Provincial University of Chinese Medicine, increase R&D investment, focus on transforming research achievements into competitive advantages, and expedite the company's product entry into overseas markets.

The company's management team members attended the meeting as observers.